Hyponatremia is a typical side effect of antiseizure drugs from the dibenzazepine family. The study investigated the prevalence of hyponatremia in patients with epilepsy who were treated with eslicarbazepine. We aimed to determine the prevalence of hyponatremia, reveal the factors leading to the discontinuation of treatment, and identify possible risk factors for the development of hyponatremia including the dose dependency. The medical records of 164 patients with epilepsy taking eslicarbazepine in our center were analyzed. The overall prevalence of hyponatremia was 30.5%. The prevalence of mild hyponatremia, seen in 14%-20% of patients, was not dose dependent. The prevalence of moderate and severe hyponatremia was significantly dose dependent. The severity of hyponatremia was significantly dose dependent. Severe hyponatremia was found in 6.1% of patients. Hyponatremia was asymptomatic in the majority of cases, and in 48% did not require any management. Hyponatremia was the reason for discontinuation in 6.2% of patients. The major risk factor for developing hyponatremia was older age. The study shows that eslicarbazepine-induced hyponatremia is usually mild and asymptomatic. It usually does not require any management and seldom leads to treatment discontinuation. Hyponatremia is dose dependent. Another major risk for developing hyponatremia (besides dose) is older age.

Brno Epilepsy Center 1st Department of Neurology St Anne's University Hospital and Faculty of Medicine Masaryk University Member of ERN EpiCARE Brno Czech Republic

Central European Institute of Technology Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Berghuis B, van der Palen J, de Haan GJ, et al. Carbamazepine‐ and oxcarbazepine‐induced hyponatremia in people with epilepsy. Epilepsia. 2017;58(7):1227–1233. PubMed

Gupta DK, Bhoi SK, Kalita J, Misra UK. Hyponatremia following eslicarbazepine therapy. Seizure. 2015;29:11–14. PubMed

Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology. 2005;65(12):1976–1978. PubMed

Villanueva V, Serratosa JM, Guillamón E, et al. Long‐term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1‐year ESLIBASE retrospective study. Epilepsy Res. 2014;108(7):1243–1252. PubMed

Sperling MR, Abou‐Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial‐onset seizures: results of a phase iii, double‐blind, randomized, placebo‐controlled trial. Epilepsia. 2015;56(2):244–253. PubMed PMC

Hufnagel A, Ben‐Menachem E, Gabbai AA, Falcão A, Almeida L, Soares‐da‐Silva P. Long‐term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial‐onset seizures in adults with epilepsy: results of a 1‐year open‐label extension study. Epilepsy Res. 2013;103(2–3):262–269. PubMed

Intravooth T, Staack AM, Juerges K, Stockinger J, Steinhoff BJ. Antiepileptic drugs‐induced hyponatremia: review and analysis of 560 hospitalized patients. Epilepsy Res. 2018;143:7–10. PubMed

Habib MB, Elshafei M, Ali E, et al. Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure. Clin Case Rep [Internet]. 2021;9(11). Accessed June 10, 2023. https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4851 PubMed DOI PMC

Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine‐induced severe and symptomatic hyponatremia. Seizure. 2014;23(3):208–212. PubMed

Gandhi S, McArthur E, Mamdani MM, et al. Antiepileptic drugs and hyponatremia in older adults: two population‐based cohort studies. Epilepsia. 2016;57(12):2067–2079. PubMed

Burst V. Etiology and epidemiology of hyponatremia. In: Peri A, Thompson CJ, Verbalis JG, editors. Frontiers of Hormone Research [Internet]. S. Karger AG; 2019. p. 24–35. Accessed June 10, 2023. https://www.karger.com/Article/FullText/493234 PubMed

Shysh AC, Ismail Z, Sidhu D, Guo M, Nguyen LT, Naugler C. Factors associated with hyponatremia in patients newly prescribed citalopram: a retrospective observational study. Drugs Real World Outcomes. 2021;8(4):555–563. PubMed PMC